Clasificación en acciones
#29600
Ulisse Biomed S.p.A. is an Italy-based biotechnology enterprise specializing in... Ulisse Biomed S.p.A. is an Italy-based biotechnology enterprise specializing in healthcare diagnostics. The company develops and markets a diverse range of innovative platforms and products designed for disease detection. Central to its offerings is the Sagitta platform, which encompasses specialized tests such as Ladymed/HPV Selfy for human papillomavirus screening, CoronaMelt for identifying SARS-CoV-2, and CoronaMelt Var for detecting and genotyping SARS-CoV-2 variants. Sagitta also provides UlisseFaster, a vital reagent used for the pre-treatment of biological samples, alongside various diagnostic tools for sexually transmitted infections and for detecting HPV associated with oropharyngeal cancers. Beyond Sagitta, Ulisse Biomed boasts the NanoHybrid platform, an advanced multi-modal biomolecule system that utilizes DNA/PNA technology to directly identify specific antibodies and protein analytes from serum or whole blood samples. Its portfolio is further enhanced by the Aptavir platform, dedicated to the development and manufacturing of synthetic nucleic acid molecules aimed at curtailing the infectiousness of pathogens. Established in 2015, Ulisse Biomed S.p.A. operates from its headquarters in Udine, Italy.
Precio por acción
$0.93739396
Última sincronización: 2026-01-08
Capitalización bursátil
$20.44M
Comercio Ulisse Biomed S.p.A. (UBM)
Precio UBM con Capital del mercado a B
Capitalización de mercado de Ulisse Biomed S.p.A.(UBM)
Capitalización bursátil: $20.44M
A fecha de August 2026, Ulisse Biomed S.p.A. tiene una capitalización de mercado de $20.44M. Esto convierte a Ulisse Biomed S.p.A. en la 29600th empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de Ulisse Biomed S.p.A. desde 2021 hasta 2026
UBM en comparación con los más populares 5 títulos stocks
| Precio por UBM |
|
Activo B |
Capital del mercado en B |
Resultados |
|
|
|
|
$5.307T
|
+25,962,013.18%
|
|
|
|
|
$4.551T
|
+22,264,070.89%
|
|
|
|
|
$4.154T
|
+20,324,863.37%
|
|
|
|
|
$3.589T
|
+17,556,640.26%
|
|
|
|
|
$2.797T
|
+13,683,298.50%
|
